Wesfarmers Centre of Vaccines & Infectious Diseases
What is an adaptive trial?
Team
Infectious Disease Implementation Research projects
Resources
Extra whooping cough shot to protect your bub
Professor Tom Snelling
Reports and Findings
Same-visit hepatitis C testing and treatment to accelerate cure among people who inject drugs (the QuickStart Study): A cluster randomised cross-over trial protocol
Despite universal access to government-funded direct-acting antivirals in 2016, the rate of hepatitis C treatment uptake in Australia has declined substantially. Most hepatitis C is related to injecting drug use; reducing the hepatitis C burden among people who inject drugs is, therefore, paramount to reach hepatitis C elimination targets.
Published research Infectious Diseases Infectious Disease Implementation Research Subsite: Wesfarmers Centre of Vaccines and Infectious DiseasesSMS-based interventions for improving child and adolescent vaccine coverage and timeliness: a systematic review
The aim of this review was to investigate the impact of short message service (SMS)-based interventions on childhood and adolescent vaccine coverage and timeliness.
Published research Immunisation Infectious Disease Implementation Research Subsite: Wesfarmers Centre of Vaccines and Infectious DiseasesEpidemiology and Outcomes of Neonatal Sepsis: Experience from a Tertiary Australian NICU
Neonatal sepsis is associated with significant mortality and morbidity. Low-middle-income countries are disproportionately affected, but late-onset sepsis still occurs in up to 20% of infants <28 weeks in high-income countries. Understanding site-specific data is vital to guide management.
Published research Infectious Disease Implementation Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases Child and adolescent healthFinancial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults
Untreated hepatitis C virus (HCV) infection can result in cirrhosis and hepatocellular cancer. Direct-acting antiviral (DAA) therapies are highly effective and have few side effects compared to older interferon-based therapy. Despite the Australian government providing subsidised and unrestricted access to DAA therapy for chronic HCV infection, uptake has not been sufficient to meet the global target of eliminating HCV as a public health threat by 2030.
Published research Infectious Disease Implementation Research Subsite: Wesfarmers Centre of Vaccines and Infectious Diseases